The industry-leading SomaScan® Assay will help revolutionize your research
SomaLogic boasts industry-leading reliability metrics that include sensitivity, specificity, and reproducibility, with coefficients of variation <5%
Most protein assays excel in only one or two areas. The SomaScan Assay, however, is the first and only platform that enables 11,000 protein measurements from a 55-µL sample. That’s more than double the number of proteins compared to any other proteomic assay and with the greatest number of orthogonally confirmed protein reagents in the proteomics industry.
Reproducible (<5% CV)
Because the SomaScan Assay does not rely on polyclonal antibodies, which are variable, SomaLogic leads the industry with a dependably low median coefficient of variation (CV) of ~5%. Additionally, it is…
While most protein assays rely on a variation of the ELISA sandwich approach, the SomaScan Assay relies on kinetics: non-specific…
A tiered dilution approach is used to measure proteins of very high abundance and very low abundance separately, such…
The tiered approach used for SomaScan measurements enables the detection of very rare proteins consistently without…
Largest menu (11,000 analytes)
By far the largest commercial proteomic assay on the market, the SomaScan Assay provides thousands of protein…
High throughput(over 1,000 samples/day)
Our workflow is massively multiplexed using a scalable system of robotics. Today, we can assay over 1,000 clinical samples per day at our CLIA-certified lab at U.S. World Headquarters.
A single platform for discovery, validation, and development
The SomaScan® Assay uses Slow Off-Rate Modified Aptamers (called SOMAmer® Reagents) to provide highly reproducible measurements of circulating proteins from a single sample of plasma, serum, urine, and other sample types.
SOMAmer® Reagents are synthetic, ssDNA sequences with protein-like appendages that tightly bind a specific protein target.
Developed by SELEX
Precise requirements for binding and durability are controlled via a directed evolution process called SELEX.
The SomaScan Assay outperforms antibody – and mass spec-based proteomic approaches
We are using all major proteomics approaches including antibody-based and MS-based methods in addition to SomaScan because of their complementarity. SomaScan stands out, however, with the largest coverage of plasma proteome, no sensitivity limitation, excellent reproducibility/precision, and impressive throughput.”
Source: Customer Response to Tech Validate Survey
Key SomaLogic publications
PublicationSeminal SomaScan publication
Introduces the SomaScan Assay and demonstrates how chemically modified aptamers can be used to detect and discover biomarkers.
PublicationImproving SELEX with modified aptamers
Describes how additional functional groups were used to increase the diversity of aptamers in the SELEX process, expanding to 3,000 targets.
PublicationSOMAmer Reagent crystal structure
Reports the crystal structure of a SOMAmer Reagent binding PDGF-BB. Unlike traditional aptamers, the SOMAmer Reagent utilizes hydrophobic interactions and mimics the natural receptor.